A greater percentage of patients receiving Febuxostat versus Allopurinol achieved complete resolution of tophi. Thus, the reduction in serum
benefits and harms of allocation to aspirin (A) versus control (C) using a allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase
allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad) versus active comparator
The hazard ratio (febuxostat versus allopurinol) in a Cox proportional hazards model was assessed for non-inferiority (limit of 13) in an on-
allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad) versus active comparator
by A Charlton 2024 Cited by 3ence when compared to allopurinol. Several provincial plans The net clinical benefits of febuxostat versus allopurinol in patients.
by R Seth 2024 Cited by 137probenecid (one trial); We deemed allopurinol versus placebo the main comparison, and allopurinol versus febuxostat and versus
Patients with gout and cardiovascular disease were randomized to febuxostat (n = 3,098) versus allopurinol (n = 3,092). Febuxostat was given at
versus allopurinol – the FAST study – as part of the febuxostat pharmacovigilance plan. allopurinol, probenecid and allopurinol probenecid.
Ziegler sisters
Scout Taylor Compton versus Danielle Harris
Danielle bregoli versus woah Vicky